CCNU in the treatment of canine epitheliotropic lymphoma

Laurel E. Williams, Kenneth M. Rassnick, Helen T. Power, Susan E. Lana, Kirsten E. Morrison-Collister, Katherine S Hansen, Jeffrey L. Johnson

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

This retrospective study examined the use of CCNU (1-[2-chloroethyl]3- cyclohexyl-1-nitrosurea) in 36 dogs with epitheliotropic lymphoma. Thirty-one (86%) dogs had the cutaneous form of disease, and 5 (14%) dogs had the oral form of disease. Nineteen (51%) dogs were treated with other chemotherapeutic agents before receiving CCNU. All dogs had detectable disease at the time CCNU therapy was initiated. Dogs received a median starting CCNU dosage of 70 mg/m 2 (range, 50-100 mg/m2). The median number of treatments administered was 3 (range, 1-12 treatments). After the initial treatment, the CCNU dosage was adjusted in 9 of 26 (35%) dogs in which CCNU was continued: 7 had dosage reductions, and 2 had dosage escalations. Twenty-eight of 36 (78%) dogs had a measurable response to CCNU for a median duration of 106 days (95% confidence interval [CI], 75-182). Six dogs (17%) had a complete response, including 5 dogs with the cutaneous form and 1 dog with the oral form. Twenty-two dogs (61%) had a partial response, including 20 dogs with the cutaneous form and 2 dogs with the oral form, for a median duration of 88 days (95% CI, 62-170). Toxicoses after CCNU chemotherapy included myelosuppression in up to 29% of the dogs, gastrointestinal signs in up to 22% of the dogs, and liver enzyme activity increases in up to 86% of the dogs. This study demonstrates that CCNU chemotherapy can be considered a reasonable option for the treatment of canine epitheliotropic lymphoma in dogs.

Original languageEnglish (US)
Pages (from-to)136-143
Number of pages8
JournalJournal of Veterinary Internal Medicine
Volume20
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Fingerprint

mycosis fungoides
Canidae
Lymphoma
Dogs
dogs
Therapeutics
mouth
dosage
drug therapy
confidence interval
Mouth Diseases
Confidence Intervals

Keywords

  • Dog
  • Medicine chemotherapy
  • Mycosis fungoides

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Williams, L. E., Rassnick, K. M., Power, H. T., Lana, S. E., Morrison-Collister, K. E., Hansen, K. S., & Johnson, J. L. (2006). CCNU in the treatment of canine epitheliotropic lymphoma. Journal of Veterinary Internal Medicine, 20(1), 136-143. https://doi.org/10.1892/0891-6640(2006)20[136:CITTOC]2.0.CO;2

CCNU in the treatment of canine epitheliotropic lymphoma. / Williams, Laurel E.; Rassnick, Kenneth M.; Power, Helen T.; Lana, Susan E.; Morrison-Collister, Kirsten E.; Hansen, Katherine S; Johnson, Jeffrey L.

In: Journal of Veterinary Internal Medicine, Vol. 20, No. 1, 01.2006, p. 136-143.

Research output: Contribution to journalArticle

Williams, LE, Rassnick, KM, Power, HT, Lana, SE, Morrison-Collister, KE, Hansen, KS & Johnson, JL 2006, 'CCNU in the treatment of canine epitheliotropic lymphoma', Journal of Veterinary Internal Medicine, vol. 20, no. 1, pp. 136-143. https://doi.org/10.1892/0891-6640(2006)20[136:CITTOC]2.0.CO;2
Williams, Laurel E. ; Rassnick, Kenneth M. ; Power, Helen T. ; Lana, Susan E. ; Morrison-Collister, Kirsten E. ; Hansen, Katherine S ; Johnson, Jeffrey L. / CCNU in the treatment of canine epitheliotropic lymphoma. In: Journal of Veterinary Internal Medicine. 2006 ; Vol. 20, No. 1. pp. 136-143.
@article{1f68060063814044bdf980c6f0fe7290,
title = "CCNU in the treatment of canine epitheliotropic lymphoma",
abstract = "This retrospective study examined the use of CCNU (1-[2-chloroethyl]3- cyclohexyl-1-nitrosurea) in 36 dogs with epitheliotropic lymphoma. Thirty-one (86{\%}) dogs had the cutaneous form of disease, and 5 (14{\%}) dogs had the oral form of disease. Nineteen (51{\%}) dogs were treated with other chemotherapeutic agents before receiving CCNU. All dogs had detectable disease at the time CCNU therapy was initiated. Dogs received a median starting CCNU dosage of 70 mg/m 2 (range, 50-100 mg/m2). The median number of treatments administered was 3 (range, 1-12 treatments). After the initial treatment, the CCNU dosage was adjusted in 9 of 26 (35{\%}) dogs in which CCNU was continued: 7 had dosage reductions, and 2 had dosage escalations. Twenty-eight of 36 (78{\%}) dogs had a measurable response to CCNU for a median duration of 106 days (95{\%} confidence interval [CI], 75-182). Six dogs (17{\%}) had a complete response, including 5 dogs with the cutaneous form and 1 dog with the oral form. Twenty-two dogs (61{\%}) had a partial response, including 20 dogs with the cutaneous form and 2 dogs with the oral form, for a median duration of 88 days (95{\%} CI, 62-170). Toxicoses after CCNU chemotherapy included myelosuppression in up to 29{\%} of the dogs, gastrointestinal signs in up to 22{\%} of the dogs, and liver enzyme activity increases in up to 86{\%} of the dogs. This study demonstrates that CCNU chemotherapy can be considered a reasonable option for the treatment of canine epitheliotropic lymphoma in dogs.",
keywords = "Dog, Medicine chemotherapy, Mycosis fungoides",
author = "Williams, {Laurel E.} and Rassnick, {Kenneth M.} and Power, {Helen T.} and Lana, {Susan E.} and Morrison-Collister, {Kirsten E.} and Hansen, {Katherine S} and Johnson, {Jeffrey L.}",
year = "2006",
month = "1",
doi = "10.1892/0891-6640(2006)20[136:CITTOC]2.0.CO;2",
language = "English (US)",
volume = "20",
pages = "136--143",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - CCNU in the treatment of canine epitheliotropic lymphoma

AU - Williams, Laurel E.

AU - Rassnick, Kenneth M.

AU - Power, Helen T.

AU - Lana, Susan E.

AU - Morrison-Collister, Kirsten E.

AU - Hansen, Katherine S

AU - Johnson, Jeffrey L.

PY - 2006/1

Y1 - 2006/1

N2 - This retrospective study examined the use of CCNU (1-[2-chloroethyl]3- cyclohexyl-1-nitrosurea) in 36 dogs with epitheliotropic lymphoma. Thirty-one (86%) dogs had the cutaneous form of disease, and 5 (14%) dogs had the oral form of disease. Nineteen (51%) dogs were treated with other chemotherapeutic agents before receiving CCNU. All dogs had detectable disease at the time CCNU therapy was initiated. Dogs received a median starting CCNU dosage of 70 mg/m 2 (range, 50-100 mg/m2). The median number of treatments administered was 3 (range, 1-12 treatments). After the initial treatment, the CCNU dosage was adjusted in 9 of 26 (35%) dogs in which CCNU was continued: 7 had dosage reductions, and 2 had dosage escalations. Twenty-eight of 36 (78%) dogs had a measurable response to CCNU for a median duration of 106 days (95% confidence interval [CI], 75-182). Six dogs (17%) had a complete response, including 5 dogs with the cutaneous form and 1 dog with the oral form. Twenty-two dogs (61%) had a partial response, including 20 dogs with the cutaneous form and 2 dogs with the oral form, for a median duration of 88 days (95% CI, 62-170). Toxicoses after CCNU chemotherapy included myelosuppression in up to 29% of the dogs, gastrointestinal signs in up to 22% of the dogs, and liver enzyme activity increases in up to 86% of the dogs. This study demonstrates that CCNU chemotherapy can be considered a reasonable option for the treatment of canine epitheliotropic lymphoma in dogs.

AB - This retrospective study examined the use of CCNU (1-[2-chloroethyl]3- cyclohexyl-1-nitrosurea) in 36 dogs with epitheliotropic lymphoma. Thirty-one (86%) dogs had the cutaneous form of disease, and 5 (14%) dogs had the oral form of disease. Nineteen (51%) dogs were treated with other chemotherapeutic agents before receiving CCNU. All dogs had detectable disease at the time CCNU therapy was initiated. Dogs received a median starting CCNU dosage of 70 mg/m 2 (range, 50-100 mg/m2). The median number of treatments administered was 3 (range, 1-12 treatments). After the initial treatment, the CCNU dosage was adjusted in 9 of 26 (35%) dogs in which CCNU was continued: 7 had dosage reductions, and 2 had dosage escalations. Twenty-eight of 36 (78%) dogs had a measurable response to CCNU for a median duration of 106 days (95% confidence interval [CI], 75-182). Six dogs (17%) had a complete response, including 5 dogs with the cutaneous form and 1 dog with the oral form. Twenty-two dogs (61%) had a partial response, including 20 dogs with the cutaneous form and 2 dogs with the oral form, for a median duration of 88 days (95% CI, 62-170). Toxicoses after CCNU chemotherapy included myelosuppression in up to 29% of the dogs, gastrointestinal signs in up to 22% of the dogs, and liver enzyme activity increases in up to 86% of the dogs. This study demonstrates that CCNU chemotherapy can be considered a reasonable option for the treatment of canine epitheliotropic lymphoma in dogs.

KW - Dog

KW - Medicine chemotherapy

KW - Mycosis fungoides

UR - http://www.scopus.com/inward/record.url?scp=30944470331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30944470331&partnerID=8YFLogxK

U2 - 10.1892/0891-6640(2006)20[136:CITTOC]2.0.CO;2

DO - 10.1892/0891-6640(2006)20[136:CITTOC]2.0.CO;2

M3 - Article

C2 - 16496933

AN - SCOPUS:30944470331

VL - 20

SP - 136

EP - 143

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 1

ER -